Candel Therapeutics IncNASDAQ:CADL
- LAST PRICE7.1305
- TODAY'S CHANGE (%)-0.1595 (-2.1879%)
- Bid / Lots7.1100/ 4
- Ask / Lots7.2000/ 4
- Open / Previous Close7.3500 / 7.2900
- Day Range
- 52 Week Range
- Volume100,228
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CADL |
|---|---|---|
| 09:32 ET | 7300 | 7.3 |
| 09:34 ET | 2835 | 7.28 |
| 09:36 ET | 100 | 7.24 |
| 09:38 ET | 1271 | 7.2259 |
| 09:39 ET | 1090 | 7.195 |
| 09:43 ET | 856 | 7.19 |
| 09:45 ET | 100 | 7.185 |
| 09:48 ET | 2900 | 7.15 |
| 09:50 ET | 1788 | 7.19 |
| 09:54 ET | 8596 | 7.21 |
| 09:56 ET | 100 | 7.31 |
| 09:57 ET | 1296 | 7.29 |
| 09:59 ET | 100 | 7.215 |
| 10:01 ET | 475 | 7.28 |
| 10:03 ET | 332 | 7.29 |
| 10:08 ET | 700 | 7.25 |
| 10:12 ET | 3258 | 7.35 |
| 10:14 ET | 9600 | 7.35 |
| 10:15 ET | 1452 | 7.3959 |
| 10:17 ET | 100 | 7.4 |
| 10:19 ET | 200 | 7.35 |
| 10:21 ET | 100 | 7.375 |
| 10:24 ET | 3155 | 7.27 |
| 10:26 ET | 2500 | 7.285 |
| 10:35 ET | 200 | 7.21 |
| 10:39 ET | 1760 | 7.24 |
| 10:42 ET | 500 | 7.3099 |
| 10:44 ET | 288 | 7.27 |
| 10:46 ET | 6680 | 7.26 |
| 10:48 ET | 100 | 7.21 |
| 10:50 ET | 2800 | 7.195 |
| 10:51 ET | 1445 | 7.18 |
| 10:53 ET | 157 | 7.17 |
| 10:57 ET | 1000 | 7.17 |
| 11:00 ET | 200 | 7.1101 |
| 11:02 ET | 450 | 7.17 |
| 11:09 ET | 26736 | 7.13 |
| 11:13 ET | 100 | 7.1 |
| 11:22 ET | 483 | 7.1 |
| 11:26 ET | 425 | 7.19 |
| 11:27 ET | 188 | 7.13 |
| 11:29 ET | 252 | 7.1305 |
Jun 11, 2024
Candel Therapeutics to Join Russell 3000(R) Index, from 8:00AM ET on Tuesday Jun 11, 2024 by Dow Jones
8:00AM ET on Tuesday Jun 11, 2024 by Dow Jones
Jun 3, 2024
May 30, 2024
DJ Candel Therapeutics Gets FDA's Orphan-Drug Status for Glioma Treatment, from 8:30AM ET on Thursday May 30, 2024 by Dow Jones
8:30AM ET on Thursday May 30, 2024 by Dow JonesFDA Grants Orphan Drug Designation for CAN-3110 for the Treatment of Recurrent High-Grade Glioma, from 8:00AM ET on Thursday May 30, 2024 by Dow Jones
8:00AM ET on Thursday May 30, 2024 by Dow Jones
May 23, 2024
DJ Candel Therapeutics Shares Pop 39% After Lung-Cancer Treatment Yields Higher Survival in Trial, from 7:16PM ET on Thursday May 23, 2024 by Dow Jones
7:16PM ET on Thursday May 23, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Candel Therapeutics Inc | 216.9M | -5.5x | --- |
Prelude Therapeutics Inc | 214.2M | -2.1x | --- |
Aldeyra Therapeutics Inc | 221.6M | -7.3x | --- |
Pyxis Oncology Inc | 223.2M | -2.8x | --- |
Acrivon Therapeutics Inc | 223.9M | -2.4x | --- |
Design Therapeutics Inc | 209.6M | -3.6x | --- |
Company Information
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The Company has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform and is in ongoing clinical trials in non-small cell lung cancer (NSCLC), borderline resectable pancreatic cancer, and localized, non-metastatic prostate cancer. CAN-3110 is the lead product candidate from the HSV platform and is in an ongoing investigator-sponsored phase I clinical trial in recurrent high-grade glioma (HGG). Its enLIGHTEN Discovery Platform leverages human biology and advanced analytics to create new viral immunotherapies for solid tumors.
Contact Information
- Headquarters
- 117 Kendrick Street,, Suite 450NEEDHAM, MA, United States 02494
- Phone
- 617-916-5445
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Paul Manning
- President, Chief Executive Officer, Director
- Paul Tak
- Interim Chief Financial Officer
- Charles Schoch
- Chief Scientific Officer
- Francesca Barone
- Vice President - Development Leader
- Christopher Matheny
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $216.9M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 29.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.29 |
Book Value | $0.44 |
P/E Ratio | -5.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
